Piper Sandler Maintains Overweight on Day One Biopharmaceutical, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro has maintained an Overweight rating on Day One Biopharmaceutical (NASDAQ:DAWN) and kept the price target at $40.
March 26, 2024 | 11:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler reaffirms an Overweight rating on Day One Biopharmaceutical with a $40 price target.
The maintenance of an Overweight rating and a $40 price target by a reputable analyst like Joseph Catanzaro from Piper Sandler suggests a positive outlook on Day One Biopharmaceutical's stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90